Exagen reports record 2025 revenue $66-67M, up 19-20% YoY; cash at $32M

EXAGEN INC.

2025-FY EPS reported -$0.93 revenue$66,575,000

Q4 2025 revenue $16-17M (17-24% YoY growth); full-year revenue $66-67M (19-20% YoY growth).
AVISE CTD volume 136,000-137,000 (+11% vs 2024); TTM ASP $441-$445, up >$30 from 2024.
Year-end cash $32M, up $10M from 2024; results in line with prior guidance.
CEO cites topline growth from volume and ASP expansion; new AVISE platform enhancements launched.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.